Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats

Journal of Ethnopharmacology

Volumn 186, Issue , 2016, Pages 224-233

  Li, Lei ^a   Dong, Pengda ^a   Hou, Congjia ^b   Cao, Fangyuan ^a   Sun, Shouli ^a   He, Fa ^a   Song, Yanping ^a   Li, Sen ^a   Bai, Yuhua ^a   Zhu, Daling ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Daqing Fifth Hospital   (China)

^c Bio pharmaceutical Key Laboratory of Heilongjiang Province   (China)

Author keywords

HSYA; hypoxic pulmonary arterial hypertension; proliferation of PASMCs; pulmonary artery remodelling; right ventricular hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLINE; EOSIN; HEMATOXYLIN; HYDROXYSAFFLOR YELLOW A; KI 67 ANTIGEN; NIFEDIPINE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; CHALCONE; QUINONE DERIVATIVE;

ADULT; AIRWAY REMODELING; ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOTROPHY; HYPOXIA-INDUCED PULMONARY HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL SURVIVAL; COMPLICATION; CYTOLOGY; DRUG EFFECTS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYTOTHERAPY; SAFFLOWER; SMOOTH MUSCLE CELL; VASCULAR REMODELING; WISTAR RAT;

ANIMALS; CARTHAMUS TINCTORIUS; CELL SURVIVAL; CELLS, CULTURED; CHALCONE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA; MALE; MYOCYTES, SMOOTH MUSCLE; PHYTOTHERAPY; PULMONARY ARTERY; QUINONES; RATS, WISTAR; VASCULAR REMODELING;

EID: 84963665042     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2016.04.004     Document Type: Article

References (19)

1. Y. Bai, P. Lu, C. Han, C. Yu, M. Chen, F. He, D. Yi, and L. Wu Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius L. and its vasodilatation effects on pulmonary artery Molecules 17 12 2012 14918 14927
2. J.I. Benisty Pulmonary hypertension Circulation 106 2002 192 194
3. K. Boutet, D. Montani, X. Jaïs, A. Yaïci, O. Sitbon, G. Simonneau, and M. Humbert Review: Therapeutic advances in pulmonary arterial hypertension Ther. Adv. Respir. Dis. 2 4 2008 249 265
4. E.D. Burg, C.V. Remillard, and X.J. Yuan Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmaco -therapeutic implications Br. J. Pharmacol. 153 1(S1) 2008 S99 S111
5. K.M. Chin, M. Kingman, and J.A.D. Lemos Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension Am. J. Cardiol. 101 11 2008 1669 1672
6. Committee of National Pharmacopoeia Pharmacopoeia of People's Republic of China (I) 2010 Chemical Industry Press Beijing 141 142
7. B.K. Dahal, D. Kosanovic, P.K. Pamarthi, A. Sydykov, Y.J. Lai, R. Kast, H. Schirok, J.P. Stasch, H.A. Ghofrani, N. Weissmann, F. Grimminger, W. Seeger, and R.T. Schermuly Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension Eur. Respir. J. 36 4 2010 808 818
8. Z.M. Feng, J. He, J.S. Jiang, Z.H. Chen, Y.N. Yang, and P.CH. Zhang NMR solution structure study of the representative component hydroxysafflor yellow A and other quinochalcone C-glycosides from Carthamus tinctorius J. Nat. Prod. 76 2 2013 270 274
9. R.M. FULTON, E.C. HUTCHINSON, and A.M. JONES Ventricular weight in cardiac hypertrophy Br. Heart J. 14 1952 413 420
10. B. Han, and H. Zhao Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice Neurochem. Res. 35 2010 107 113
11. H. He, X. Yang, M. Shi, X. Zeng, J. Yang, L. Wu, and L. Li Protective effects of hydroxysafflor yellow A on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats J. Pharm. Pharmacol. 60 2008 115 123
12. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension New Engl. J. Med. 35 2004 1425 1436
13. R. Naeije, and A. Manes The right ventricle in pulmonary arterial hypertension Eur. Respir. Rev. 23 2014 476 487
14. National Researh Council National Institutes of Health. Guide for the Care and Use of Laboratory Animals 1996 NIH publication 85-23
15. P.H. Nie, L. Zhang, W.H. Zhang, W.F. Rong, and J.M. Zhi The effects of hydroxysafflor yellow A on blood pressure and cardiac function J. Ethnopharmacol. 139 2012 746 750
16. G.G. Pietra, F. Capron, S. Stewart, O. Leone, M. Humbert, I.M. Robbins, and et al. Pathologic assessment of vasculopathies in pulmonary hypertension J. Am. Coll. Cardiol. 43 12 2004 25S 32S
17. J. Tian, W. Jang, Z. Wang, C. Wang, and F. Fu Effects of safflower flavone on local cerebral ischemia and thrombosis formation in rats Chin. Tradit. Herb. Drugs 34 2003 741 743
18. Y.C. Tien, J.Y. Lin, C.H. Lai, C.H. Kuo, W.Y. Lin, C.H. Tsai, F.J. Tsai, Y.C. Cheng, W.H. Peng, and C.Y. Huang Carthamus tinctorius L. prevents LPS-induced TNFalpha signaling activation and cell apoptosis through JNK1/2-NFkappaB pathway inhibition in H9c2 cardiomyoblast cells J. Ethnopharmacol. 130 2010 505 513
19. L. Zhang, P.H. Nie, G.H. Zhang, W.F. Rong, and J.M. Zhi Endothelium independent vasodilation effect of hydroxysafflor yellow A in thoracic aorta of Wistar rats J. Med. Plants Res. 5 2011 2187 2191